Pharmaceutical Technology

JUNE 5, 2023

PharmaEssentia may be entitled to receive certain milestone payments along with royalties based on sales of the product. Pint-Pharma will obtain and maintain all marketing authorisations and will commercialise BESREMi in the region. It holds orphan drug designation in the US to treat PV.

Marketing 130

Marketing Licensing Licensing Sales 130

Pharmaceutical Technology

MAY 8, 2023

Under the terms of the license and commercialisation deal, Dr. Reddy’s will get licence for the development and commercialisation of toripalimab in India, Panama, Peru, Colombia, South Africa, Brazil, Argentina, Chile, Uruguay, and Mexico. Junshi Biosciences may get an aggregate of up to $728.3m

Development 130

Development Marketing Licensing Licensing 130

BioPharma Reporter

MAY 6, 2021

The next step will be to start a rolling submission for a Biologics License Application (BLA) for its COVID-19 vaccine with the FDA this month. Moderna has reported the first profitable quarter in the companyâs history: after 10 years of research and several billion dollars of investment in its mRNA platform.

Licensing 97

Licensing Licensing Vaccination Vaccine 97

Pharmaceutical Technology

MAY 31, 2023

Stealth BioTherapeutics has made an exclusive licensing agreement with Pharmanovia for the commercialisation of its elamipretide to treat Barth syndrome.

Licensing 245

Licensing Licensing Sales Development 245

Pharmaceutical Technology

JANUARY 19, 2023

Acute myeloid leukemia (AML) is part of a market of blood malignancies that commercial cell therapies have not managed to penetrate yet. None of these products are in a registrational trial, and as such, GlobalData does not anticipate their entry into the AML market earlier than 2028.

Marketing 130

Marketing Gene Editing Production Sales 130

Pharmaceutical Technology

MAY 1, 2023

The NDA is supported by the data package licensed to Ocumension by Nicox as well as the Phase III clinical trial in China. Zerviate, 0.24% was compared to emedastine difumarate ophthalmic solution, 0.05%, an antihistamine, which is marketed under undeb Emadine brand name.

Licensing 162

Licensing Licensing Sales Packaging 162

BioPharma Reporter

SEPTEMBER 6, 2022

Emergence Therapeutics has become the tenth company to license ADC technology from Synaffix. The deal has a total potential value of up to US$360m, plus royalties on commercial sales.

Licensing 52

Licensing Licensing Sales Regulation 52

Pharmaceutical Technology

OCTOBER 28, 2022

On 24 October, American vaccine developer Vaxcyte shared positive topline data from a Phase I/II study of its multivalent conjugate pneumococcal vaccine VAX-24 , bringing the 24-valent pneumococcal jab one step closer to market. VAX-24 has forecasted sales of $21 million in the same year. Competition in an increasingly heated market.

Vaccination 162

Vaccination Vaccine Marketing Bacteria 162

Pharmaceutical Technology

MAY 12, 2023

BlissBio has the potential to earn up to $2bn in commercial milestone payments, as well as royalties on sales if Eisai exercises its option to license the drug. The drug became a blockbuster last year, with sales reaching $1.9bn, up from $599m in 2021. targeting ADC.

Clinical Trials 162

Clinical Trials Clinical Trials Licensing Licensing 162

pharmaphorum

JULY 8, 2022

Swedish rare disease specialist Sobi is paying $55 million upfront to license rights to ADC Therapeutics’ lymphoma therapy Zynlonta – approved in the US last year – in Europe and other international markets. The post Sobi bolsters blood division via $435m ADC licensing deal appeared first on.

Licensing 52

Licensing Licensing Sales Marketing 52

pharmaphorum

NOVEMBER 15, 2022

Lantheus’ pipeline-building drive in radiopharma has continued with a $260 million upfront deal to license rights to two oncology candidates from POINT Biopharma. billion in milestone payments to POINT if the two radiotherapeutics get FDA approval and meet commercial objectives, plus royalties on net sales.

Licensing 52

Licensing Licensing FDA Approval Trials 52

pharmaphorum

FEBRUARY 11, 2022

The company has just claimed its first approval for the drug in Canada – under the Sohonos brand name – as a treatment for the ultra-rare genetic disorder fibrodysplasia ossificans progressiva (FOP), but was forced to withdraw its marketing application for the drug in the US last summer after a request for more data.

Sales 97

Sales Pharma Companies Branding Cosmetics 97

pharmaphorum

AUGUST 18, 2021

Akili already has the first and only FDA cleared video game-based digital therapeutic (DTx) for children with attention-deficit hyperactivity disorder (ADHD), but is looking to add to its range via a licensing deal with Australia’s TALi Digital. . TALi is also in line for royalties on sales.

Licensing 62

Licensing Licensing Sales FDA Approval 62

Pharmaceutical Technology

JUNE 1, 2023

The company will also be entitled to receive up to $40m in additional payments linked to development and sales milestones. The licensing agreement also requires Viatris Japan to pay up to double-digit percentage royalties based on the net sales of the product in Japan.

Sales 130

Sales Licensing Licensing Marketing 130

Pharmaceutical Technology

DECEMBER 19, 2022

Innate is also eligible to receive a total of up to $1.43bn (€1.35bn) in preclinical, clinical, regulatory and commercial milestone payments and royalty payments on net sales in the future. On choosing the candidate, the company will oversee the complete development, production and marketing.

Development 264

Development Engineer Clinical Trials Clinical Trials 264

pharmaphorum

NOVEMBER 10, 2021

The drug was the first in the oral CGRP inhibitor class to get an prevention indication approved by the FDA in May, and that has helped accelerate its rollout, bringing in $336 million in US sales for Biohaven so far this year. The post Pfizer strikes $1.2bn licensing deal for Biohaven migraine drug appeared first on.

Licensing 52

Licensing Licensing Drugs Sales 52

pharmaphorum

DECEMBER 7, 2021

billion in milestones depending on sales levels if the antisense-based drug reaches the market. Onpattro and Tegsedi are also being developed for ATTR-cardiomyopathy, so eplontersen may well have to jostle for market share in an increasingly crowded market if its gets approved.

Licensing 57

Licensing Licensing Drugs Marketing 57

Pharmaceutical Technology

DECEMBER 26, 2022

LegoChem Biosciences and Amgen have signed a multi-target research collaboration and license agreement to develop antibody-drug conjugates (ADC). The company will also be eligible for tiered royalties as a percentage of global commercial sales of the products.

Antibody 130

Antibody Development Drugs Licensing 130

pharmaphorum

AUGUST 10, 2021

Seagen was a pioneer in the development of ADC drugs, and has successfully brought two to market – Adcetris (brentuximab vedotin) for various type of lymphoma and Padcev (enfortumab vedotin) for bladder cancer – so its decision to tap RemeGen’s platform is an endorsement for the Chinese biotech. Sales last year grew by a third to $1.7

Licensing 52

Licensing Licensing Antibody Sales 52

Pharmaceutical Technology

MAY 16, 2023

The deal encompasses Vivotif and Vaxchora, both marketed vaccines for the prevention of typhoid fever and cholera respectively, and a Phase III vaccine candidate for the prevention of Chikungunya virus, which have now all been transferred to Bavarian Nordic.

Vaccination 130

Vaccination Vaccine Licensing Licensing 130

The Pharma Data

JANUARY 6, 2021

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

Licensing 52

Licensing Licensing Development Clinical Trials 52

Pharma Business Blog

JULY 2, 2021

a wholesale distribution license “WDA”) from a third party country like e.g. Switzerland, US and as per 1 January 2022 the U.K.is not sufficient, in order to sell medicinal products in Germany and/or to the German market. Several EU Member States have already implemented similar local rules, i.e. not only the German market is affected.

Sales 52

Sales Drugs Licensing Licensing 52

Pharmaceutical Technology

MARCH 23, 2023

Pfizer recently announced an agreement to acquire Seagen, a biotech company based in the US with four marketed oncology therapeutic agents and a rich pipeline. This figure derives from net product sales in addition to revenues gained from royalties and licensing agreements.

Licensing 147

Licensing Licensing Sales Trials 147

Drug Discovery World

OCTOBER 4, 2023

Our focus in the near term is on the registration, approval and commercialization of Kinselby in the European Union, Switzerland and the UK and we are on track to file for European Marketing Approval of Kinselby in Q1 2024, to rapidly bring this therapy into clinical use. 4SC is

Marketing 52

Marketing Drugs Clinical Trials Clinical Trials 52

Pharmaceutical Technology

JULY 4, 2022

Brii Biosciences (Brii Bio) has exercised an option for the acquisition of exclusive development and marketing rights for Vir Biotechnology’s investigational antibody, VIR-3434, for Hepatitis B in Greater China, under a partnership agreement.

Antibody 279

Antibody Genotype Licensing Licensing 279

Pharmacy Checkers

DECEMBER 5, 2019

A new Chinese law (in effect as of December 1, 2019) makes third-party online platform medicine sales legal, appropriately ends a draconian definition of counterfeit drugs, and effectively decriminalizes personal drug importation, but with a lot of gray! Buying Drugs Online from Retail Platforms is Legal.

Sales 64

Sales Medicine Pharmacy Drugs 64

pharmaphorum

FEBRUARY 3, 2022

India’s Dr Reddy’s Laboratories has joined the growing list of pharma companies that are looking to tap into the market for medical cannabis, buying German developer Nimbus Health for an undisclosed sum.

Licensing 117

Licensing Licensing Marketing Medicine 117

Pharmaceutical Technology

AUGUST 10, 2022

Furthermore, Cerevance will simultaneously out-license a discovery-stage programme to Merck under the partnership. Cerevance will also potentially receive royalty payments on sales of approved products resulting from the partnership. “We

Licensing 223

Licensing Licensing Sales Development 223

XTalks

APRIL 3, 2024

While Soliris had its market launch 17 years ago with $3.2 billion in sales in 2023, Ultomiris was approved in 2018 and generated $3 billion in revenue last year. Competitors in the PNH market include Novartis, which won approval for its factor B inhibitor Fabhalta (iptacopan), the first oral pill for PNH treatment, late last year.

FDA Approval 102

FDA Approval Sales Trials Development 102

Pharmaceutical Technology

FEBRUARY 14, 2023

Precision oncology firm Corbus Pharmaceuticals and CSPC Megalith Biopharmaceutical have entered an exclusive licensing agreement for the latter’s new clinical stage antibody drug conjugate (ADC), CRB-701 (SYS6002). upfront payment and eligible for royalties on net sales. CSPC Megalith is a subsidiary of CSPC Pharmaceutical Group.

Antibody 130

Antibody Drugs Clinical Development Licensing 130

Pharmaceutical Technology

MAY 10, 2023

According to the US government, Gilead had repeatedly refused to license patents related to PrEP research undertaken by the Department of Health and Human Services’ (HHS) Centers for Disease Control and Prevention (CDC). Gilead markets both Truvada and its successor Descovy.

FDA Approval 264

FDA Approval Drugs Containment Licensing 264

Pharmaceutical Technology

AUGUST 4, 2022

According to the deal, Poseida will offer either exclusive rights or options to Roche for developing and marketing various allogeneic CAR-T programmes in its portfolio targeting hematologic malignancies. Furthermore, Roche will oversee the late-stage clinical development and worldwide marketing of all products under the alliance.

Development 147

Development Clinical Trials Clinical Trials Gene Therapy 147

Pharmaceutical Technology

JANUARY 31, 2023

Daewoong Pharmaceutical has entered an exclusive licensing agreement with CS Pharmaceuticals (CSP) for Bersiporocin, a first-in-class PRS inhibitor, in the Greater China region for Idiopathic Pulmonary Fibrosis (IPF).

Clinical Trials 130

Clinical Trials Clinical Trials Licensing Licensing 130

Pharmaceutical Technology

MAY 25, 2023

Adalvo has entered a strategic licensing agreement with Swiss pharmaceutical company EQL Pharma for Mellozzan (melatonin) outside Europe and the US. The deal includes licence income for specified individual key markets along with profit sharing on future Mellozzan sales.

Hormones 130

Hormones Engineer Licensing Licensing 130

Pharmaceutical Technology

AUGUST 2, 2022

Sosei Heptares , a corporate brand of Sosei Group Corporation, has signed a new drug discovery partnership and option-to-license agreement with AbbVie for discovering, developing and marketing new therapies for neurological ailments. Additionally, AbbVie will make tiered royalty payments based on global product sales to Sosei Heptares.

Development 147

Development Licensing Licensing Branding 147

The Pharma Data

DECEMBER 29, 2020

Shapiro as Vice President of Sales, effective January 1, 2021. Sean is a seasoned sales executive who has successfully launched several aesthetic devices in the industry, and we look forward to leveraging his extensive experience as we prepare for the commercial launch of our RAP technology during the first half of next year.”

Sales 52

Sales Containment Production Licensing 52

The Pharma Data

DECEMBER 20, 2020

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Licensing 40

Licensing Licensing Life Science Manufacturing 40